Table 1.

Patient characteristics

Variablen%
Age, median (range), y 55 (23-69) — 
Sex   
56 
44 
Conditioning intensity   
Myeloablative 12 75 
Reduced 25 
Disease   
AML 12 75 
MDS 25 
Donor   
Matched related 37 
Matched unrelated 44 
Mismatched related (haploidentical) 19 
Status at HCT   
CR1 44 
CR2 12 
Not in remission 44 
Cytogenetic risk   
Monosomal (+) 56 
Monosomal (−) 44 
Molecular   
TP53 (+) 37 
TP53 (−) 44 
TP53 (n/a) 19 
BM blast % at relapse (AML + MDS), median (range) 21.5 (5-92) 
BM blast % at relapse (AML), median (range) 26.5 (5-92) 
Prior GVHD before Pembrolizumab   
No 10 63 
Yes 37 
On immune suppression at pembrolizumab start   
No 11 69 
Yes 31 
Time of relapse post-HCT (range), d 168.5 (66-1064) 
Variablen%
Age, median (range), y 55 (23-69) — 
Sex   
56 
44 
Conditioning intensity   
Myeloablative 12 75 
Reduced 25 
Disease   
AML 12 75 
MDS 25 
Donor   
Matched related 37 
Matched unrelated 44 
Mismatched related (haploidentical) 19 
Status at HCT   
CR1 44 
CR2 12 
Not in remission 44 
Cytogenetic risk   
Monosomal (+) 56 
Monosomal (−) 44 
Molecular   
TP53 (+) 37 
TP53 (−) 44 
TP53 (n/a) 19 
BM blast % at relapse (AML + MDS), median (range) 21.5 (5-92) 
BM blast % at relapse (AML), median (range) 26.5 (5-92) 
Prior GVHD before Pembrolizumab   
No 10 63 
Yes 37 
On immune suppression at pembrolizumab start   
No 11 69 
Yes 31 
Time of relapse post-HCT (range), d 168.5 (66-1064) 

CR1, first complete remission; CR2, second complete remission; F, female; M, male.

or Create an Account

Close Modal
Close Modal